DE602004006367C5 - Polymorphe Form von Rifaximin als Antibiotikum - Google Patents
Polymorphe Form von Rifaximin als Antibiotikum Download PDFInfo
- Publication number
- DE602004006367C5 DE602004006367C5 DE602004006367.3T DE602004006367T DE602004006367C5 DE 602004006367 C5 DE602004006367 C5 DE 602004006367C5 DE 602004006367 T DE602004006367 T DE 602004006367T DE 602004006367 C5 DE602004006367 C5 DE 602004006367C5
- Authority
- DE
- Germany
- Prior art keywords
- water
- rifaximin
- temperature
- suspension
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims description 13
- 229960003040 rifaximin Drugs 0.000 title claims description 12
- 230000003115 biocidal effect Effects 0.000 title description 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 239000011800 void material Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- 239000000725 suspension Substances 0.000 claims 7
- 235000019441 ethanol Nutrition 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 4
- 238000005406 washing Methods 0.000 claims 4
- 239000011877 solvent mixture Substances 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 229950011175 aminopicoline Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- RAFHKEAPVIWLJC-OQQFTUDCSA-N Rifamycin O Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC5(OCC(=O)O5)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C RAFHKEAPVIWLJC-OQQFTUDCSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- -1 pomades Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- RAFHKEAPVIWLJC-TWYIRNIGSA-N z67lem9p1w Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N2)C)OC)C(C(=C3O)C)=C1C1=C3C(=O)C2=C[C@]11OCC(=O)O1 RAFHKEAPVIWLJC-TWYIRNIGSA-N 0.000 claims 1
- 239000013078 crystal Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B6/00—Heating by electric, magnetic or electromagnetic fields
- H05B6/02—Induction heating
- H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
- H05B6/12—Cooking devices
- H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
- H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B6/00—Heating by electric, magnetic or electromagnetic fields
- H05B6/02—Induction heating
- H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
- H05B6/12—Cooking devices
- H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
- H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
- H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Electromagnetism (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
nichtig
Description
- Der X. Zivilsenat des Bundesgerichtshofs hat auf die mündliche Verhandlung vom 7. August 2018 durch den Vorsitzenden Richter Prof. Dr. Meier-Beck, die Richter Gröning, Dr. Grabinski und Dr. Bacher und die Richterin Dr. Kober-Dehm für Recht erkannt:
- Auf die Berufung wird das Urteil des 3. Senats (Nichtigkeitssenats) des Bundespatentgerichts vom 28. Juni 2016 abgeändert.
- Das
europäische Patent 1 557 421 wird im Umfang der Patentansprüche 1, 2, 10 bis 12 und 15 mit Wirkung für die Bundesrepublik Deutschland für nichtig erklärt. - Die Kosten des Rechtsstreits werden der Beklagten auferlegt.
- Von Rechts wegen Tatbestand: 1 Die Beklagte ist Inhaberin des mit Wirkung für die Bundesrepublik Deutschland erteilten
europäischen Patents 1 557 421 (Streitpatents), das am 9. März 2004 unter Inanspruchnahme einer italienischen Priorität vom 7. November 2003 angemeldet worden ist und eine Kristallform des Antibioti¬ kums Rifaximin betrifft. Das Streitpatent hat ferner Verfahren zur Herstellung dieser Rifaximin-Form sowie diese enthaltende Zusammensetzungen zum Ge¬ genstand. Die nebengeordneten Patentansprüche 1, 3, 8, 10, 11, 13 und 15,
Claims (15)
- nichtig
- nichtig
- Verfahren zur Herstellung von Rifaximin α, das umfasst: Umsetzen eines molaren Äquivalentes von Rifamycin O mit einem Überschuss von 2-Amino-4-methylpyridin in einer Lösungsmittelmischung von Wasser und Ethylalkohol in einem Volumenverhältnis zwischen 1:1 und 2:1 für einen Zeitraum zwischen 2 und 8 Stunden bei einer Temperatur zwischen 40 und 60°C, Behandeln der Reaktionsmasse bei Raumtemperatur mit einer Lösung von Ascorbinsäure in einer Mischung von Wasser, Ethylalkohol und konzentrierter wässriger Salzsäure, Einstellen des pH der Reaktionsmasse auf pH 2,0 mit einer konzentrierten wässrigen Lösung von Salzsäure, Filtrieren der Dispersion, Waschen jedes resultierenden Feststoffes mit der Wasser/Ethylalkohol-Lösungsmittelmischung, um Roh-Rifaximin zu erhalten, Reinigen des Roh-Rifaximins durch Lösen davon in Ethylalkohol bei einer Temperatur zwischen 45°C und 65°C, Ausfällen des Roh-Rifaximins durch Zugabe von Wasser und Verringerung der Temperatur der Suspension auf zwischen 0°C und 50°C unter Rühren für einen Zeitraum zwischen 4 und 36 Stunden, Filtrieren der Suspension, Waschen des resultierenden Feststoffes mit Wasser und Trocknen davon unter Vakuum oder unter Normaldruckbedingungen mit oder ohne Trocknungsmittel bei einer Temperatur zwischen Raumtemperatur und 105°C für einen Zeitraum zwischen 2 und 72 Stunden.
- Verfahren nach
Anspruch 3 , worin das 2-Amino-4-methylpyridin 2,0 bis 3,5 molaren Äquivalenten entspricht. - Verfahren nach
Anspruch 3 , worin das Wasser, welches zugegeben wird, um das Roh-Rifaximin auszufällen, in einer Gewichtsmenge zwischen 15% und 70% bezogen auf die Gewichtsmenge des Ethylalkohols, welcher zum Lösen verwendet wird, vorliegt. - Verfahren nach
Anspruch 3 zur Herstellung von Rifaximin α, worin nach der Zugabe von Wasser zum Roh-Rifaximin, die Temperatur auf einen Wert zwischen 28°C und 32°C verringert wird, um den Beginn der Kristallisation zu bewirken, das Rühren der resultierenden Suspension bei einer Temperatur zwischen 40°C und 50°C für einen Zeitraum zwischen 6 und 24 Stunden erfolgt, das Abkühlen der Suspension auf 0°C für einen Zeitraum zwischen 15 Minuten und einer Stunde erfolgt, das Filtrieren der Suspension, das Waschen des resultierenden Feststoffes mit Wasser und das Trocknen des gewaschenen Feststoffes, bis ein Wassergehalt unterhalb von 4,5% erreicht ist, erfolgt. - Verfahren nach
Anspruch 6 , worin der Wassergehalt zwischen 2,0 und 3,0% beträgt. - Verfahren zur Herstellung von Rifaximin α, das umfasst: Suspendieren von Rifaximin γ in einer Lösungsmittelmischung von Ethylalkohol/Wasser in einem Volumenverhältnis von 7:3, Erwärmen der Suspension auf eine Temperatur zwischen 38°C und 50°C unter Rühren für einen Zeitraum zwischen 6 und 36 Stunden, Filtrieren der Suspension, Waschen des resultierenden Feststoffes mit Wasser und Trocknen des gewaschenen Feststoffes, bis ein Wassergehalt von weniger als 4,5% erreicht wird.
- Verfahren nach
Anspruch 8 , worin der Wassergehalt zwischen 2,0% und 3,0% beträgt. - nichtig
- nichtig
- nichtig
- Zusammensetzung, die eine vorgegebene Menge von Rifaximin α in Kombination mit Exzipienten, welche für die topische Anwendung geeignet sind, umfasst.
- Zusammensetzung nach
Anspruch 13 , worin die Exzipienten für die Herstellung von Salben, Pomaden, Cremes, Gelen und Lotionen geeignet sind. - nichtig
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20032144 | 2003-11-07 | ||
| IT002144A ITMI20032144A1 (it) | 2003-11-07 | 2003-11-07 | Forme polimorfe di rifaximina, processi per ottenerle e |
| EP04005541A EP1557421B1 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Form von Rifaximin als Antibiotikum |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE602004006367D1 DE602004006367D1 (de) | 2007-06-21 |
| DE602004006367T2 DE602004006367T2 (de) | 2007-09-06 |
| DE602004006367C5 true DE602004006367C5 (de) | 2019-04-04 |
Family
ID=33187382
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004019298T Expired - Lifetime DE602004019298D1 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Formen von Rifaximin als Antibiotica |
| DE602004019296T Expired - Lifetime DE602004019296D1 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Formen von Rifaximin als Antibiotica |
| DE602004006367.3T Expired - Lifetime DE602004006367C5 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Form von Rifaximin als Antibiotikum |
| DE04005541T Pending DE04005541T1 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Formen von Rifaximin als Antibiotika |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004019298T Expired - Lifetime DE602004019298D1 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Formen von Rifaximin als Antibiotica |
| DE602004019296T Expired - Lifetime DE602004019296D1 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Formen von Rifaximin als Antibiotica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE04005541T Pending DE04005541T1 (de) | 2003-11-07 | 2004-03-09 | Polymorphe Formen von Rifaximin als Antibiotika |
Country Status (37)
| Country | Link |
|---|---|
| US (5) | US7045620B2 (de) |
| EP (6) | EP1676848B1 (de) |
| JP (5) | JP2005139161A (de) |
| KR (4) | KR20050043589A (de) |
| CN (4) | CN1613858A (de) |
| AR (3) | AR043547A1 (de) |
| AT (3) | ATE361927T1 (de) |
| AU (2) | AU2004200964A1 (de) |
| BR (2) | BRPI0402382A (de) |
| CA (2) | CA2460384A1 (de) |
| CL (1) | CL2004000498A1 (de) |
| CO (1) | CO5560083A1 (de) |
| CY (3) | CY1108017T1 (de) |
| DE (4) | DE602004019298D1 (de) |
| DK (3) | DK1557421T3 (de) |
| ES (3) | ES2320161T3 (de) |
| HR (2) | HRP20040265A2 (de) |
| IL (2) | IL160798A0 (de) |
| IT (1) | ITMI20032144A1 (de) |
| JO (1) | JO2470B1 (de) |
| MA (1) | MA27069A1 (de) |
| MD (1) | MD3653G8 (de) |
| ME (1) | ME00424B (de) |
| MX (2) | MXPA04002353A (de) |
| NO (1) | NO334950B1 (de) |
| NZ (1) | NZ531622A (de) |
| PL (3) | PL1557421T3 (de) |
| PT (3) | PT1676847E (de) |
| RS (4) | RS54571B1 (de) |
| RU (1) | RU2270200C2 (de) |
| SI (3) | SI1676848T1 (de) |
| TN (2) | TNSN04044A1 (de) |
| TW (1) | TWI285107B (de) |
| UA (1) | UA86384C2 (de) |
| WO (1) | WO2005044823A2 (de) |
| YU (1) | YU24804A (de) |
| ZA (1) | ZA200401948B (de) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US20080262024A1 (en) * | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
| US7902206B2 (en) * | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US7923553B2 (en) * | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
| US7906542B2 (en) * | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
| PL1698630T3 (pl) * | 2005-03-03 | 2014-12-31 | Alfasigma Spa | Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych |
| ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| SI2054066T1 (sl) | 2006-08-02 | 2015-08-31 | Salix Pharmaceuticals, Inc. | Postopki za zdravljenje radiacijskega enteritisa |
| ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
| US8633234B2 (en) * | 2006-09-22 | 2014-01-21 | Cipla Limited | Rifaximin |
| US20080161337A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Chronic Prostatitis |
| US20080159987A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Restless Legs Syndrome |
| ITMI20071241A1 (it) * | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
| AU2016203925B2 (en) * | 2007-07-06 | 2016-10-20 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| PL2011486T5 (pl) * | 2007-07-06 | 2016-09-30 | Lupin Ltd | Farmaceutyczne kompozycje rifaksyminy |
| AU2008273699A1 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| CN102015725B (zh) * | 2008-02-25 | 2014-10-22 | 萨利克斯药品有限公司 | 利福昔明的多种形式及其用途 |
| US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| EP3563850A1 (de) | 2008-02-26 | 2019-11-06 | Salix Pharmaceuticals, Ltd. | Verfahren zur behandlung von darmerkrankungen |
| US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
| HRP20140939T1 (hr) | 2008-05-07 | 2014-11-21 | Salix Pharmaceuticals, Ltd. | Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva |
| AU2009297562B2 (en) | 2008-09-26 | 2015-04-23 | Alfasigma S.P.A. | Agent for preventing and/or treating functional gastrointestinal disorder |
| ES2972135T3 (es) | 2008-10-02 | 2024-06-11 | Salix Pharmaceuticals Inc | Tratamiento de encefalopatía hepática usando rifaximina |
| US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| US20100317681A1 (en) * | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
| US12285414B2 (en) | 2008-10-02 | 2025-04-29 | Salix Pharmaceuticals, Inc. | Methods of treating hepatic encephalopathy |
| US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| CA2745980C (en) | 2008-12-10 | 2017-10-31 | Cipla Limited | Rifaximin complexes |
| IT1397617B1 (it) * | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
| NZ596851A (en) * | 2009-06-02 | 2013-10-25 | Salix Pharmaceuticals Ltd | Methods of treating hepatic encephalopathy |
| KR20120062897A (ko) | 2009-09-13 | 2012-06-14 | 샐릭스 파마슈티컬스 리미티드 | 과민성 장 증후군(ｉｂｓ)의 치료방법 |
| UA110199C2 (xx) * | 2009-10-27 | 2015-12-10 | Lupin Ltd | Тверда дисперсія рифаксиміну |
| WO2011061748A1 (en) * | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
| MX2012005883A (es) | 2009-11-23 | 2012-10-09 | Cipla Ltd | Composicion topica en espuma. |
| EP2401282B2 (de) † | 2009-12-28 | 2017-01-04 | Silvio Massimo Lavagna | Verfahren zur herstellung von amorphem rifaximin |
| AU2011218129A1 (en) | 2010-02-18 | 2012-08-23 | Board Of Regents Of The University Of Texas System | Methods for treating infection |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| AU2011261283B2 (en) * | 2010-06-03 | 2015-05-14 | Salix Pharmaceuticals, Ltd. | New forms of rifaximin and uses thereof |
| US8883795B2 (en) * | 2010-06-16 | 2014-11-11 | Apotex Pharmachem Inc. | Polymorphic forms of Rifaximin |
| GEAP202112996A (en) * | 2010-07-12 | 2021-09-10 | Salix Pharmaceuticals Ltd Us | Formulations of rifaximin and uses thereof |
| WO2012035544A2 (en) | 2010-09-13 | 2012-03-22 | Sequent Scientific Ltd. | A novel polymorphic form of rifaximin and process for its preparation |
| IT1403847B1 (it) * | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
| WO2012060675A1 (es) * | 2010-11-05 | 2012-05-10 | Interquim, S.A. De C.V. | Proceso para la preparación de rifaximina amorfa |
| WO2012076832A1 (en) * | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
| EP2672970B1 (de) | 2011-02-11 | 2018-08-01 | Salix Pharmaceuticals, Ltd. | Formen von rifaximin und anwendungen davon |
| WO2012150561A1 (en) | 2011-05-02 | 2012-11-08 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
| ITMI20110890A1 (it) * | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
| WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| US20130184302A1 (en) | 2011-11-02 | 2013-07-18 | Enoch Bortey | Methods for treating irritable bowel syndrome (ibs) and infections |
| JP2013184902A (ja) * | 2012-03-06 | 2013-09-19 | Aska Pharmaceutical Co Ltd | リファキシミン含有結晶 |
| US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| WO2014091432A1 (en) | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
| EP2971062A2 (de) | 2013-03-15 | 2016-01-20 | ALFA WASSERMANN S.p.A. | Verfahren zur diagnose von vaginalinfektionen |
| CA2897758A1 (en) | 2013-03-15 | 2014-09-18 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections |
| US20140308350A1 (en) | 2013-04-12 | 2014-10-16 | Alfa Wassermann S.P.A. | Nsaid administration and related compositions, methods and systems |
| US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
| ES2621557T3 (es) * | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
| US9765088B2 (en) | 2014-04-19 | 2017-09-19 | Granules India Limited | Process for the preparation of rifamycin derivatives |
| JP6693946B2 (ja) | 2014-05-04 | 2020-05-13 | サリックス ファーマスーティカルズ，インコーポレーテッド | Ｉｂｓ微生物叢及びその使用 |
| US9938298B2 (en) | 2014-05-12 | 2018-04-10 | Alfa Wassermann S.P.A. | Solvated crystal form of rifaximin, production, compositions and uses thereof |
| KR102318025B1 (ko) * | 2014-06-30 | 2021-10-27 | 샐릭스 파마슈티컬스 인코포레이티드 | 과민성 대장 증후군(ibs)의 재치료 방법 |
| CN104083324B (zh) * | 2014-07-10 | 2017-05-10 | 青岛动保国家工程技术研究中心有限公司 | 一种利福昔明的兽用悬乳剂及其制备方法和应用 |
| EP2982764A1 (de) | 2014-08-05 | 2016-02-10 | ALFA WASSERMANN S.p.A. | Identifizierung von Vaginalbakterien |
| CN104274391B (zh) * | 2014-10-08 | 2017-02-01 | 哈尔滨坤盟医药科技有限公司 | 一种含利福昔明的药物制剂 |
| WO2017021975A1 (en) * | 2015-08-06 | 2017-02-09 | Msn Laboratories Private Limited | Process for the preparation of crystalline forms of rifaximin |
| PL3373914T5 (pl) | 2016-03-24 | 2022-10-17 | Sandoz Ag | Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa |
| ES2700423T3 (es) | 2016-03-24 | 2019-02-15 | Sandoz Ag | Composición farmacéutica que contiene rifaximina alfa y delta |
| US9988398B2 (en) * | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
| CA3038312A1 (en) | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
| CN106632396B (zh) * | 2017-01-06 | 2019-01-11 | 成都樵枫科技发展有限公司 | γ晶型利福昔明的制备方法和用途 |
| WO2018197538A1 (en) | 2017-04-26 | 2018-11-01 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
| WO2019003076A1 (en) | 2017-06-26 | 2019-01-03 | Biofer S.P.A. | PYRIDO-IMIDAZO-RIFAMYCIN DERIVATIVES AS ANTIBACTERIAL AGENT |
| EP3902528A1 (de) * | 2018-12-19 | 2021-11-03 | Friulchem SpA | Verfahren zur herstellung einer rifaximintablette und rifaximintablette |
| CA3142214A1 (en) | 2019-06-03 | 2020-12-10 | Bausch Health Ireland Limited | Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders |
| CN114401721A (zh) | 2019-09-24 | 2022-04-26 | 博士医疗爱尔兰有限公司 | 利福昔明液体制剂 |
| US20230116647A1 (en) | 2020-03-24 | 2023-04-13 | Bausch Health Ireland Limited | Methods of treating covid-19 with rifaximin |
| WO2021229480A1 (en) * | 2020-05-15 | 2021-11-18 | Atra Pharmaceuticals Limited | Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin |
| AU2021298178A1 (en) | 2020-06-26 | 2023-02-02 | Bausch Health Ireland Limited | Targeted release rifaximin compositions |
| WO2022090490A1 (en) | 2020-10-29 | 2022-05-05 | Bausch Health Ireland Limited | Rifaximin liquid formulations for use in the treatment of sickle cell disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4241785A (en) * | 1978-07-24 | 1980-12-30 | Peerless Of America, Inc. | Heat exchangers and method of making same |
| IT1154655B (it) * | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| IT1199374B (it) * | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| CA1215976A (en) | 1984-05-15 | 1986-12-30 | Vincenzo Cannata | New process for the synthesis of imidazo rifamycins |
| IT1199413B (it) | 1984-09-26 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
| ES2075454T3 (es) * | 1990-06-29 | 1995-10-01 | Lepetit Spa | Forma cristalina pura de rifapentina. |
| CZ20022332A3 (cs) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| EP1330427A1 (de) * | 2000-10-31 | 2003-07-30 | Ciba SC Holding AG | Kristalline formen von venlafaxinhydrochlorid |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US20050262269A1 (en) | 2004-05-20 | 2005-11-24 | Pike Jimmy D | System and method for information handling system PCI express advanced switching |
| PL1698630T3 (pl) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych |
| US8633234B2 (en) | 2006-09-22 | 2014-01-21 | Cipla Limited | Rifaximin |
| WO2008115572A1 (en) | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
| ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
| AU2008273699A1 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| PL2011486T5 (pl) | 2007-07-06 | 2016-09-30 | Lupin Ltd | Farmaceutyczne kompozycje rifaksyminy |
| US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| JP2011500552A (ja) | 2007-10-10 | 2011-01-06 | ルピン・リミテッド | 胃腸障害を処置するための医薬用組み合わせおよび組成物 |
| CN102015725B (zh) | 2008-02-25 | 2014-10-22 | 萨利克斯药品有限公司 | 利福昔明的多种形式及其用途 |
-
2003
- 2003-11-07 IT IT002144A patent/ITMI20032144A1/it unknown
- 2003-12-05 US US10/728,090 patent/US7045620B2/en not_active Expired - Lifetime
-
2004
- 2004-03-09 DE DE602004019298T patent/DE602004019298D1/de not_active Expired - Lifetime
- 2004-03-09 EP EP06004220A patent/EP1676848B1/de not_active Expired - Lifetime
- 2004-03-09 CA CA002460384A patent/CA2460384A1/en not_active Abandoned
- 2004-03-09 DE DE602004019296T patent/DE602004019296D1/de not_active Expired - Lifetime
- 2004-03-09 DE DE602004006367.3T patent/DE602004006367C5/de not_active Expired - Lifetime
- 2004-03-09 DK DK04005541T patent/DK1557421T3/da active
- 2004-03-09 DK DK06004220T patent/DK1676848T3/da active
- 2004-03-09 AT AT04005541T patent/ATE361927T1/de active
- 2004-03-09 PT PT06004219T patent/PT1676847E/pt unknown
- 2004-03-09 PL PL04005541T patent/PL1557421T3/pl unknown
- 2004-03-09 PT PT04005541T patent/PT1557421E/pt unknown
- 2004-03-09 IL IL16079804A patent/IL160798A0/xx unknown
- 2004-03-09 EP EP04005541A patent/EP1557421B1/de not_active Expired - Lifetime
- 2004-03-09 ES ES06004220T patent/ES2320161T3/es not_active Expired - Lifetime
- 2004-03-09 DK DK06004219T patent/DK1676847T3/da active
- 2004-03-09 PT PT06004220T patent/PT1676848E/pt unknown
- 2004-03-09 DE DE04005541T patent/DE04005541T1/de active Pending
- 2004-03-09 ES ES06004219T patent/ES2320160T4/es not_active Expired - Lifetime
- 2004-03-09 AT AT06004220T patent/ATE421966T1/de active
- 2004-03-09 PL PL06004219T patent/PL1676847T3/pl unknown
- 2004-03-09 NZ NZ531622A patent/NZ531622A/en not_active IP Right Cessation
- 2004-03-09 EP EP06004219A patent/EP1676847B1/de not_active Expired - Lifetime
- 2004-03-09 AT AT06004219T patent/ATE421965T1/de active
- 2004-03-09 PL PL06004220T patent/PL1676848T3/pl unknown
- 2004-03-09 SI SI200431070T patent/SI1676848T1/sl unknown
- 2004-03-09 ES ES04005541T patent/ES2244364T3/es not_active Expired - Lifetime
- 2004-03-09 SI SI200431074T patent/SI1676847T1/sl unknown
- 2004-03-09 SI SI200430297T patent/SI1557421T1/sl unknown
- 2004-03-10 ZA ZA200401948A patent/ZA200401948B/xx unknown
- 2004-03-10 AU AU2004200964A patent/AU2004200964A1/en not_active Abandoned
- 2004-03-11 CO CO04022467A patent/CO5560083A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100781A patent/AR043547A1/es not_active Application Discontinuation
- 2004-03-11 MX MXPA04002353A patent/MXPA04002353A/es unknown
- 2004-03-11 CL CL200400498A patent/CL2004000498A1/es unknown
- 2004-03-16 TW TW093106943A patent/TWI285107B/zh not_active IP Right Cessation
- 2004-03-16 CN CNA2004100477623A patent/CN1613858A/zh active Pending
- 2004-03-17 KR KR1020040017892A patent/KR20050043589A/ko not_active Ceased
- 2004-03-17 JP JP2004076458A patent/JP2005139161A/ja active Pending
- 2004-03-18 RU RU2004108953/04A patent/RU2270200C2/ru active
- 2004-03-18 JO JO200433A patent/JO2470B1/en active
- 2004-03-18 HR HRP20040265 patent/HRP20040265A2/hr not_active Application Discontinuation
- 2004-03-19 BR BR0402382-0A patent/BRPI0402382A/pt not_active IP Right Cessation
- 2004-03-19 YU YU24804A patent/YU24804A/sh unknown
- 2004-03-19 TN TNP2004000044A patent/TNSN04044A1/en unknown
- 2004-03-24 MA MA27590A patent/MA27069A1/fr unknown
- 2004-04-11 UA UAA200602354A patent/UA86384C2/uk unknown
- 2004-11-04 MD MDA20060080A patent/MD3653G8/ro active IP Right Grant
- 2004-11-04 EP EP10004590A patent/EP2208730A1/de not_active Withdrawn
- 2004-11-04 CN CN2008100869308A patent/CN101260114B/zh not_active Expired - Lifetime
- 2004-11-04 RS RS20150292A patent/RS54571B1/sr unknown
- 2004-11-04 RS YUP-2006/0168A patent/RS20060168A/sr unknown
- 2004-11-04 RS RS20150291A patent/RS54569B1/sr unknown
- 2004-11-04 AU AU2004287601A patent/AU2004287601B8/en active Active
- 2004-11-04 BR BRPI0407149A patent/BRPI0407149A8/pt not_active Application Discontinuation
- 2004-11-04 ME MEP-2008-633A patent/ME00424B/me unknown
- 2004-11-04 KR KR1020077026409A patent/KR100883216B1/ko not_active Expired - Lifetime
- 2004-11-04 CN CN2008100869327A patent/CN101260115B/zh not_active Expired - Lifetime
- 2004-11-04 HR HRP20060093AA patent/HRP20060093B1/hr not_active IP Right Cessation
- 2004-11-04 EP EP04797615A patent/EP1682556A2/de not_active Withdrawn
- 2004-11-04 KR KR1020077026410A patent/KR100867751B1/ko not_active Expired - Fee Related
- 2004-11-04 KR KR1020057013910A patent/KR100855084B1/ko not_active Expired - Lifetime
- 2004-11-04 RS RS20060168A patent/RS54568B1/sr unknown
- 2004-11-04 EP EP10004589A patent/EP2210893A1/de not_active Withdrawn
- 2004-11-04 JP JP2006537252A patent/JP5199576B2/ja not_active Expired - Lifetime
- 2004-11-04 CN CN2004800030228A patent/CN1886408B/zh not_active Expired - Lifetime
- 2004-11-04 MX MXPA06002644A patent/MXPA06002644A/es active IP Right Grant
- 2004-11-04 CA CA2538546A patent/CA2538546C/en not_active Expired - Lifetime
- 2004-11-04 WO PCT/EP2004/012490 patent/WO2005044823A2/en not_active Ceased
-
2005
- 2005-05-24 US US11/135,651 patent/US20050272754A1/en not_active Abandoned
-
2006
- 2006-03-01 TN TNP2006000069A patent/TNSN06069A1/en unknown
- 2006-03-08 NO NO20061110A patent/NO334950B1/no unknown
- 2006-03-12 IL IL174271A patent/IL174271A/en active IP Right Grant
-
2007
- 2007-07-02 CY CY20071100875T patent/CY1108017T1/el unknown
- 2007-10-17 US US11/873,841 patent/US7915275B2/en not_active Expired - Lifetime
-
2009
- 2009-03-23 CY CY20091100319T patent/CY1108909T1/el unknown
- 2009-04-09 CY CY20091100414T patent/CY1108964T1/el unknown
-
2010
- 2010-11-19 JP JP2010259453A patent/JP5635376B2/ja not_active Expired - Lifetime
- 2010-11-19 JP JP2010259452A patent/JP2011057698A/ja not_active Withdrawn
-
2011
- 2011-03-04 US US13/041,348 patent/US8404704B2/en not_active Expired - Lifetime
- 2011-03-04 US US13/041,346 patent/US8173801B2/en not_active Expired - Lifetime
- 2011-06-23 AR ARP110102193A patent/AR081991A2/es not_active Application Discontinuation
- 2011-06-23 AR ARP110102194A patent/AR081992A2/es not_active Application Discontinuation
-
2014
- 2014-07-04 JP JP2014138697A patent/JP2014177500A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004006367C5 (de) | Polymorphe Form von Rifaximin als Antibiotikum | |
| DE69902244T2 (de) | Reaktivrotfarbstoffe enthaltend monochlortriazine sowie acetoxyethylsulphongruppen | |
| DE2207287B2 (de) | Verfahren zur Herstellung von Biscarboxyäthyl-germaniumsesquioxid | |
| DE692480T1 (de) | Verfahren zur Herstellung von Extrakten enthaltende polyphenalische oligomere Verbindungen von Catechin-Typ, aus pflanzenartigen Quellen, und diese erhaltene Extrakte | |
| DE1543809B2 (de) | Aminophenole und verfahren zu deren herstellung | |
| DE2535930B2 (de) | Abietinsaeureamidderivate und verfahren zu ihrer herstellung | |
| DE1569603A1 (de) | Verfahren zur Herstellung von Oxazinfarbstoffen | |
| DE2228660A1 (de) | Verfahren zur Herstellung von ein heithchen alpha Monohydroxylamino oder alpha, alpha Dihydroxylaminoanthrachinon verbindungen | |
| DE542801C (de) | Verfahren zur Herstellung von echten Kuepenfarbstoffen | |
| DE1958329C3 (de) | Verfahren zur Reinigung von Cephaloglycin | |
| DE2131153A1 (de) | Wasserloesliche antibakterielle Verbindungen unterirdischer Stollen | |
| DE1793596C3 (de) | 13-Alkyl-gona-l,3,(10)-triene. Ausscheidung aus: 1443123 | |
| DE833818C (de) | Verfahren zur Herstellung von neuen mono- und diquartaeren Salzen von Pyrimidylaminocinnolinen | |
| DE2435222C2 (de) | Verfahren zur Herstellung von N-(2-Diethylamino)-ethyl-2-methoxy-5-methylsulfonylbenzamid | |
| DE855116C (de) | Verfahren zur Herstellung von quaternaeren Ammoniumverbindungen | |
| DE526630C (de) | Verfahren zur Darstellung von Nitro- bzw. Aminoverbindungen des Pyracridons | |
| AT370722B (de) | Verfahren zur herstellung von 1-phenoxy-3-amino- 2-propanolen | |
| DE813709C (de) | Verfahren zur Herstellung von aromatischen monocyclischen Triaminokohlenwasserstoffen | |
| DE2026096A1 (de) | ||
| DE1468838C (de) | Verfahren zur Gewinnung von amphoterem Oxytetracyclin als Dihydrat | |
| AT267065B (de) | Verfahren zur Herstellung neuer Tetrazyklinderivate | |
| DE908732C (de) | Verfahren zur Herstellung von substituierten Pteridinen | |
| DE380712C (de) | Verfahren zur Herstellung von Kuepenfarbstoffen und Ausgangsstoffen dafuer | |
| DE2053117C3 (de) | 3-Amin-4,5-dehydro-cardenolide, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2020142C3 (de) | Verfahren zur Trennung von linksdrehendem Isomerem und Raceamt von 6-PhenyI-23,5,6tetrahydro-imidazo [2,1-b] thiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent |